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Comparing hospital and telephone follow-up for patients treated for Stage I endometrial cancer 94 
(ENDCAT Trial): a randomised, multicentre, non-inferiority trial 95 
 96 
ABSTRACT 97 
Objective To evaluate the effectiveness of nurse-led telephone follow-up (TFU) for Stage I endometrial 98 
cancer patients.   99 
Design Multicentre, randomised, non-inferiority trial 100 
Setting Five centres in the North West of England 101 
Sample 259 women treated for Stage I endometrial cancer attending hospital outpatient clinics for 102 
routine follow-up 103 
Methods Participants were randomly allocated to receive traditional hospital based follow-up (HFU) or 104 
nurse-led TFU.  105 
Main outcome measures Primary outcomes were psychological morbidity (State Trait Anxiety Inventory, 106 
STAI-S) and patient satisfaction with information. Secondary outcomes included patient satisfaction with 107 
service, quality of life, and time to detection of recurrence. 108 
Results STAI-S scores post-randomisation were similar between groups (mean [SD] TFU 33.0 [11·0], HFU 109 
35.5 [13.0]). The estimated between group difference in STAI was 0·7 (95%CI -1·9 to 3·3); the CI lies 110 
above the non-inferiority limit (-3·5) indicating non-inferiority of TFU. There was no significant difference 111 
between groups in reported satisfaction with information (OR 0·9, 95% CI 0·4 to 2·1, p=0·83). The HFU 112 
group were more likely to report being kept waiting for their appointment (p=0.001), that they did not 113 
need any information (p=0.003) and were less likely to report that the nurse knew about their particular 114 
case and situation (p=0.005).  115 
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Conclusions TFU provides an effective alternative to HFU for Stage I endometrial cancer patients, with 116 
no reported physical or psychological detriment. Patient satisfaction with information was high, with 117 
similar levels between groups 118 
Keywords Endometrial cancer, telephone follow-up, gynaecology, oncology, patient satisfaction, 119 
psychological morbidity 120 
Word count: 239 121 
 122 
Trial Registration Number: ISRCTN75220876. 123 
 124 
Tweetable abstract (108 characters with spaces) 125 
ENDCAT trial shows effectiveness of nurse-led telephone follow-up for Stage I endometrial cancer 126 




Most (75%) endometrial cancer patients present with Stage I disease (confined to the uterus); five year 129 
relative survival is over 70% .1,2 More than 80% of all recurrences occur during the first three years.3 130 
Historically, patients in the United Kingdom (UK) have attended hospital outpatient appointments at 131 
regular but decreasing intervals for a period of three to five years. However, routine clinical review after 132 
gynaecology malignancy demonstrates little or no survival benefit; early detection of recurrence does 133 
not improve outcome or reduce morbidity. 2–4 A European study reported one asymptomatic recurrence 134 
for every 653 routine consultations.5 Hence, there has been a call for prospective trials to evaluate 135 
alternative follow-up strategies for gynaecological cancers. 4 136 
 137 
UK Department of Health (DoH) guidance suggests that women treated for endometrial cancer should 138 
be informed about the lack of known benefit of follow-up, although retaining some degree of support 139 
post treatment.6 The National Cancer Survivorship Initiative (NCSI) was key to the Cancer Reform 140 
Strategy,7 aiming to improve services for cancer survivors in England and advocating supported self-141 
management approaches to follow-up, accompanied by risk stratification (based on clinical and 142 
individual need).8 Current follow-up practice does not meet cancer survivors’ full range of needs 8,9 A 143 
recent rapid review of service provision following cancer treatment concluded that addressing the needs 144 
of cancer survivors, particularly with the predicted increase in numbers, requires new models of follow-145 
up.10 There are also increasing financial pressures to devise more efficient care pathways. Alternative 146 
strategies include nurse-led and supported self-management approaches. A systematic review of nurse-147 
led versus conventional physician-led follow-up for patients with cancer concluded that patients are 148 
generally satisfied with nurse-led follow-up,11 and a meta-analysis concluded that nurse-led telephone 149 
follow-up (TFU) services were acceptable, appropriate and effective. 12 Patients with early stage cancers 150 
at low risk of recurrence could be empowered to take responsibility for their care if sufficiently 151 
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supported, with rapid access back to secondary care if needed.  Individual responsibility and self-152 
management have been highlighted as central principles for successful implementation of the 2015-153 
2020 strategy for improving cancer outcomes, empowering individuals to manage their own health care 154 
needs 13. However, the NCSI reported that these models needed further testing and evaluation.8 The 155 
model we proposed for Stage I endometrial cancer follow-up built on previous studies of nurse-led TFU 156 
for breast and colorectal cancer patients, 14–16 demonstrating that specialist nurses can meet the 157 
information needs and concerns of people treated for cancer, with no physical or psychological 158 
detriment.  We therefore designed a trial to test for non-inferiority of nurse-led TFU relative to 159 
traditional hospital based follow-up (HFU) following treatment for Stage I endometrial cancer. 160 
 161 
METHODS 162 
Study design and sample 163 
We carried out a two group, parallel, multicentre randomised non-inferiority trial in five hospitals in 164 
North West England.  Eligible patients had completed primary treatment for Stage I endometrial cancer 165 
and were returning to hospital outpatient clinics for routine monitoring. We excluded patients if they 166 
had hearing impairments or did not have access to a telephone. Patients were not excluded on the basis 167 
of language difficulties as this would need to be addressed regardless of study group allocation. Patient 168 
recruitment took place between 3rd January 2012 and 2nd January 2014.  169 
 170 
Randomisation and masking 171 
Patients were randomly assigned (1:1) to HFU or TFU using a computer based system. Randomisation 172 
was performed using permuted blocks, with randomly varying block sizes, within 10 strata defined by 173 
the combinations of the five hospitals and follow-up duration (less than 1 year or 1 year or more post 174 
diagnosis). The trial statistician was masked to group allocation. It was not possible to mask clinical staff 175 
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or participants as they would have been aware that follow-up care was being delivered over the 176 
telephone or in hospital clinics.    177 
 178 
Outcomes 179 
Primary outcomes were psychological morbidity and patient satisfaction with information. Secondary 180 
outcomes included patient satisfaction with service, quality of life, and time to detection of recurrence. 181 
We assessed non-inferiority in terms of effectiveness (for psychological morbidity, quality of life, and 182 
time to detection of recurrence) and superiority in terms of patient satisfaction with information and 183 
service. Time to detection of recurrence was defined as the time from randomisation to the date when 184 
recurrence was communicated to the patient; we also report the time between the first indications of a 185 
suspicion of recurrence to the date when recurrence was communicated to the patient.  186 
 187 
Psychological morbidity was measured using a standard instrument, the State Trait Anxiety Inventory 188 
(STAI).17,18 Patient satisfaction with information and service was recorded using questionnaires adapted 189 
from previous work on breast cancer patients,14  with the question used for the primary outcome being 190 
“Did you get all the information you needed at your hospital or telephone appointment?”. Participants 191 
were asked about the frequency and duration of their appointments. Baseline and post-randomisation 192 
questionnaires contained similar questions although some questions were re-worded post-193 
randomisation to reflect that patients could have had a hospital or telephone appointment. Quality of 194 
life was measured using the European Organization for Research and Treatment (EORTC) QLQ-C30 195 






Potential participants were identified by clinical staff in hospital outpatient clinics. All participants 200 
completed baseline measures prior to randomisation. Patients allocated to HFU continued to receive 201 
hospital based follow-up as per hospital policy at the study locations. This consisted of appointments 202 
every three or four months for the first two years post treatment followed by appointments at 203 
decreasing intervals (six monthly and annually) up to a period of three to five years. At the end of this 204 
period, patients were discharged to the care of their General Practitioner (GP). Although there was no 205 
standard format to hospital based consultations, they would usually include a clinical examination 206 
(bimanual examination and inspection of the vagina) and questions about any signs of recurrent disease 207 
(e.g. vaginal bleeding, unusual discharge).  In the TFU arm, a telephone intervention was administered 208 
by gynaecology oncology nurse specialists at intervals consistent with hospital policy at the study 209 
locations. At each study site, the frequency of delivery of the telephone intervention would mirror the 210 
frequency of scheduled hospital appointments for the control arm. Seven experienced gynaecology 211 
oncology nurse specialists administered the telephone intervention during the study period; these 212 
nurses had advanced practitioner roles with specialist knowledge and expertise in gynaecology. Patients 213 
were sent appointment cards with a date and time for their telephone appointments. The intervention 214 
was designed to be delivered in 20 minutes. Questions in the intervention were focused on physical, 215 
psychological and social aspects of care (Appendix S1). Training on the delivery of the intervention 216 
involved two half-day sessions, discussing issues related to telephone consultations, a detailed 217 
exploration of each intervention item and the practicalities of setting up telephone clinics.  218 
 219 
All outcome data were collected at baseline (pre-randomisation) and immediately after the next HFU or 220 
TFU appointment (post-randomisation). The post-randomisation data collection time point depended on 221 
whether women were on a three monthly, six monthly or annual follow-up schedule. Hence, the post-222 
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randomisation time point could range from three to 12 months from baseline data collection. Study 223 
participants were sent postal questionnaires, once formal written consent had been received, and were 224 
asked to return the questionnaires in pre-paid envelopes to a university address. Careful attention was 225 
paid to ensuring questionnaires were dispatched immediately post consultation to ensure women’s 226 
responses were targeted at the most recent hospital or telephone appointment. Introductory 227 
information on questionnaires instructed participants to refer to their ‘most recent appointment’. Data 228 
on signs of recurrent disease  were collected prospectively on ‘record of clinic visit’ and ‘record of 229 
telephone consultation’ proformas for all participants at all consultations throughout the study period. 230 
Participants’ attendance at the next scheduled appointment (hospital or telephone) post-randomisation 231 
acted as a trigger for posting out the post-randomisation questionnaires to study participants. A full 232 
review of all participants’ medical records was carried out at the end of the study follow-up period to 233 
ensure all pertinent data had been captured on the clinical proformas. Any indication of recurrent 234 
disease was monitored and tracked. Participants who were diagnosed with recurrence were withdrawn 235 
from intervention delivery and trial follow-up but their clinical trajectory was monitored. Hence, data on 236 
time to detection of recurrence could be reported.  237 
 238 
Sample size 239 
The sample size was based on a pre-stated margin of non-inferiority (3.5) for the intervention effect on 240 
the STAI-S and data (SD 10) from a previous trial of TFU for breast cancer patients.14 We planned for 80% 241 
power, a 5% significance level, and allowed for 20% attrition; the target sample size was 128 participants 242 
per group. For the co-primary outcome of ‘satisfaction with information’ it was calculated that this 243 
sample size would provide 80% power to detect an OR of at least 2.25 using ordinal regression 244 
techniques (5% significance level) based on control percentages of: ‘very satisfied’ 54%, ‘satisfied’ 39% 245 
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and ‘not very satisfied’ or ‘very unsatisfied’ 7%, approximate values from our previous trial; however the 246 
phrasing of the question was subsequently changed for use in ENDCAT. 14 247 
 248 
Statistical methods 249 
Analysis was performed using SPSS (V 22) and Stata (V 13). Demographic and baseline characteristics 250 
were summarised using: mean (standard deviation), or median (inter-quartile range), as appropriate, if 251 
quantitative (continuous or count); median (inter-quartile range) or frequency (percentage), as 252 
appropriate, if ordinal; frequency (percentage) if categorical. Characteristics of participants and non-253 
participants were compared using chi-square test or independent samples t-test, as appropriate. The 254 
primary statistical analysis of psychological morbidity (STAI S-anxiety) scores was based on an 255 
instrumental variables regression analysis using the intervention group factor as instrument, with 256 
participation/non-participation in the allocated follow-up appointment type at first follow-up as 257 
mediator (a ‘complier-adjuster’ causal analysis).  This is the approach which was used in our previous 258 
breast cancer trial and enables comparison of findings between the two trials.14 The model used also 259 
included the following baseline covariates to improve statistical efficiency: age, level of education 260 
and/or occupational group, hospital (randomisation stratum), follow-up duration (less than or at least 261 
one year post diagnosis at the time of recruitment), STAI S-anxiety, and STAI T-anxiety. Linear modelling, 262 
adjusting for the same set of factors, was used for a comparable analysis of the effect of intervention 263 
arm using ‘as treated’, ‘as randomised’ and ‘per-protocol’ (i.e. including only those who had their first 264 
post-randomisation appointment in line with the randomisation) populations. For the analysis of 265 
satisfaction with information received, ordinal logistic regression was used; those who did not need 266 
information were excluded, although a sensitivity analysis was performed to investigate the impact of 267 
handling this group differently (e.g. including them with those who reported that they got none of the 268 
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information they needed).  Adjustment was for the same baseline factors as for the STAI-S, except the 269 
STAI measures were not included whereas the satisfaction with information was included.  270 
 271 
Similar approaches were used for the following secondary outcome measures: linear modelling for 272 
overall satisfaction with service and ordinal logistic regression for satisfaction with individual aspects of 273 
service; logistic regression for patient information needs; instrumental variables regression for EORTC 274 
QLQ-C30 and EORTC QLQ-EN24 subscales. Adjustment used the same of baseline factors, but replacing 275 
the STAI measures with the baseline measure of the corresponding outcome. For satisfaction with 276 
individual aspects of service, the categories ‘strongly agree’ and ‘agree’ were merged, as were the 277 
categories ‘strongly disagree’ and ‘disagree’, due to sparse categories.   For any categorical outcome 278 
measures, if categories remained sparse, Fisher’s exact test was used (not adjusting for baseline factors).  279 
Inferential results are presented as 95% confidence intervals (CIs), with p-value when testing superiority; 280 
for testing, two-sided tests with a 5% significance level were used. 281 
 282 
Exploratory subgroup analyses for the primary outcomes were performed by adding the relevant 283 
interaction terms to the model for the following pre-specified factors: routine follow-up interval at 284 
recruitment (<6 months vs ≥6 months); age (<70 vs ≥70); level of education (no qualification vs some 285 
qualification without degree vs degree); work status (actively working vs not actively working); 286 
occupational group. A p-value of <0.1 was deemed suggestive of a potential differential intervention 287 
effect across subgroups. 288 
 289 
RESULTS 290 
We recruited 259 participants; 129 were randomised to TFU and 130 to HFU (Figure 1). As patients had 291 
repeat visits in outpatient clinics, some patients declined consent on one occasion but asked to be 292 
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considered at subsequent appointments. It was challenging to obtain accurate data on the numbers of 293 
such individuals; some will have subsequently consented but many will have remained as ‘pending’. 294 
Figure 1 contains accurate data on number of appointments but, in attempting to avoid double 295 
counting, the number of known refusers (n=92) may reflect an under-estimate as it excludes any 296 
remaining as ‘pending’ or ‘missed’. Nine randomised women did not have subsequent follow-up 297 
appointments (Figure 1) due to non-attendance (n=5), illness (n=2) and death (n=2).    298 
 299 
Insert Figure 1 here 300 
 301 
Participants were a median age of 65 years and a median of 12 months from diagnosis, with most (63%) 302 
on three or four month routine follow-up schedules; 51% were less than one year post surgery. Socio-303 
demographic and treatment characteristics of the study sample are shown in Table 1. Seventy 304 
participants who were eligible for inclusion but refused participation were willing to provide socio-305 
demographic details; non-participants were more likely to be from Black, Asian and Minority ethnic 306 
groups (p=0·019), not actively working (p=0·047), from non-skilled occupational classes (p=0·039), and 307 
had lower levels of education (p=0·060). The main reasons reported for non-participation included 308 
reassurance provided by clinical examinations, too soon after surgery and family members preferring 309 
patients to continue with HFU. 310 
 311 
Insert Table 1 here 312 
STAI-S scores at baseline (mean [SD] TFU 33.5 [11·3], HFU 35.9 [12.4]) were similar to scores post 313 
randomisation (mean [SD] TFU 33.0 [11·0], HFU 35.5 [13.0]). Using ‘adjusted for treatment received’ the 314 
estimated between group difference in STAI was 0·7 (95%CI -1·9 to 3·3); the CI lies above the non-315 
inferiority limit (-3·5) indicating non-inferiority of TFU (Figure 2). Sensitivity analysis using alternative 316 
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‘analysis sets’ (‘as treated’, ‘as randomised’ and ‘per protocol’) all showed very similar results, 317 
supporting the conclusion of non-inferiority of TFU (Figure 2).  318 
 319 
Insert Figure 2 here 320 
 321 
There was no significant difference in reported satisfaction with information at the most recent 322 
appointment between groups (OR 1·1, 95% CI 0·5 to 2·4, p=0·89), with 75/96 (78%) of the TFU group and 323 
62/78 (79%) of the HFU group who expressed an opinion reporting that they got all the information they 324 
needed (Table S1).  However, more participants in the HFU group than the TFU group (27·8% vs. 13·5%) 325 
stated that they did not need any information (p=0·003) and, when a sensitivity analysis was performed 326 
including these as ‘got none of the information I needed’, this showed a significant between-groups 327 
difference in reported satisfaction with information at the most recent appointment (OR 2·0, 95% CI 1·1 328 
to 3·5, p=0·019) . 329 
 330 
Regardless of group allocation, participants were highly satisfied with the service they had received and 331 
there were no significant differences between groups (mean [SD] TFU 9·2 [1·5], HFU 8·9 [1·7], p=0·58, 332 
95%CI adjusted mean difference -0·5 to 0·3). Overall, participants considered that their appointments 333 
had been ‘about right’ in terms of both frequency and duration, with no significant differences between 334 
randomised groups (p=0·76 for frequency, p=0·20 for duration). Participants in the HFU arm were more 335 
likely to indicate that they had been kept waiting for their appointments (p=0·001). Participants in the 336 
TFU arm were more likely to indicate that the person they spoke to paid attention to what they were 337 
saying (p=0·042), that they could express themselves and ask questions (p=0·016) and that the person 338 
they spoke to knew about their particular case (p=0·005) (Table 2). Information needs did not differ 339 
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significantly between groups for any item (Table 3). Overall, information about familial risk, self-care, 340 
and sexual attractiveness and sexual function were the most prevalent information needs reported. 341 
 342 
Insert Table 2 here 343 
Insert Table 3 here 344 
 345 
There were no significant differences between groups for quality of life in relation to the EORTC QLQ-346 
C30. Only one single item showed between group differences with participants in the HFU arm more 347 
likely to report problems with constipation (p=0·035) (Table S2). For the QLQ-EN24 there were no 348 
significant differences between groups (Table S3).  349 
 350 
Ten (4%) participants, five in each group, had a recurrence during the study period; one participant in 351 
each group died as a result of their cancer.  Seven recurrences were distant; three in the TFU group and 352 
four in the HFU group.  All recurrences were symptomatic. Symptoms included abdominal pain/swelling 353 
(n=6), vaginal bleeding (n=3) and back pain (n=1). All recurrences presented as interval events, with 354 
patients presenting symptoms to their GP (n=6) or contacting a nurse specialist (n=4) between 355 
scheduled appointments. The times from randomisation to diagnosis of recurrence were variable but 356 
not dissimilar in both groups (TFU median 307 days, range 48-662 days; HFU 172 days, 99-436 days) and 357 
the corresponding times from reporting symptoms (TFU median seven days, range 3-18 days; HFU nine 358 
days 3-70 days) were also not dissimilar.  359 
 360 
For the five planned subgroup analyses on the two primary outcomes, there was no significant subgroup 361 
effect on the STAI, nor on satisfaction with information received except work status at recruitment 362 
(p=0.080; OR 4.92, 95%CI 0.83 to 29.3). This suggested that those in work in the HFU arm were relatively 363 
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less satisfied with information received than those in work in the TFU arm but this pattern was not 364 
observed amongst those not working. 365 
 366 
DISCUSSION  367 
Main Findings 368 
The results of the ENDCAT trial were similar to those of a previous breast cancer trial and colorectal 369 
cancer pilot trial that used the same primary outcome measures.14,16 The ENDCAT study findings indicate 370 
that specialist nurses are able to deliver a follow-up service over the telephone for Stage I endometrial 371 
cancer patients; TFU was non-inferior to HFU. Hence, nurse-led TFU can replace, or complement, 372 
doctor-led HFU without increasing patient anxiety or reducing overall satisfaction with information and 373 
service. Furthermore, there was evidence that participants preferred the TFU process as telephone 374 
appointments were more likely to be on time and patients felt more able to express themselves and ask 375 
more questions. There was no evidence to suggest that diagnosis of recurrence was delayed by TFU. 376 
Although recurrences were few (n=10), as would be expected in a low risk group, none of the 377 
recurrences were detected by clinical examination of asymptomatic patients; all recurrences were 378 
symptomatic and interval events.  379 
 380 
Strengths and Limitations 381 
Our study is the only trial of nurse-led telephone follow-up for endometrial cancer patients that has 382 
been published to date.  The study was conducted in the North West of England, although we see no 383 
reason why the findings should not be generalisable to other NHS regions. The geographical locations 384 
were diverse in terms of populations and ethnic diversity, although this was not represented in the 385 
sample, which was predominantly white British. Although ethnic group was associated with refusal to 386 
participate, numbers of eligible women from minority ethnic groups was low overall. This may reflect a 387 
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more international problem of under-representation of minority groups in cancer clinical trials21, 22. 388 
Although more white women are diagnosed with endometrial cancer in England than other ethnic 389 
minority groups, age standardised incidence rates are similar for white and South Asian women and are 390 
higher for black and Chinese women23. Hence, the low numbers of women from ethnic minority groups 391 
eligible for recruitment cannot be readily explained and can be considered a limitation. For practical 392 
reasons, and limitations to the funding period, it was not possible to recruit all participants immediately 393 
after their first post-treatment outpatient appointment. Although 51% of women were less than one 394 
year post surgery, many would have experienced a number of hospital outpatient appointments and this 395 
may have biased outcomes.  Given that women would have experienced at least one hospital 396 
appointment prior to recruitment it is not possible to state when the introduction of TFU would be most 397 
beneficial or if the findings are generalisable to the first follow-up appointment.  There may also have 398 
been a carry-over effect with participants reporting on a change of appointment type rather than 399 
reporting purely on telephone follow-up 400 
 401 
Interpretation 402 
On an international level, nurse-led and TFU approaches are increasingly advocated. A recent survey in 403 
South West England indicated that nurse-led TFU had similar levels of patient satisfaction to 404 
conventional doctor-led follow-up, 24 providing further support for a shift away from traditional 405 
approaches. It may not be practical to suggest that all patients with early stage endometrial cancer are 406 
followed up post treatment by specialist nurses. Resource limitations and workloads may inhibit broad 407 
implementation. However, we now have increasing evidence that TFU is non-inferior to HFU and 408 
patients could be offered a choice of follow-up regime. In this study we mirrored the frequency of 409 
hospital appointments to enhance research rigour. In clinical practice it may be that appointment 410 
frequency can be negotiated with patients based on their preferences and patients may benefit from 411 
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more flexible approaches to follow-up care. Patients may prefer one or two hospital appointments 412 
before TFU is implemented and further research is needed to determine the most appropriate time 413 
points at which to implement TFU. 414 
 415 
Busy hospital clinics and ever increasing numbers of cancer survivors indicate that historical practices 416 
need to change and nurse-led TFU may not go far enough in addressing the challenge of meeting the 417 
needs of millions of cancer survivors within limited resources.  Self-management approaches, where 418 
patients are discharged back to primary care on completion of treatment, may become standard 419 
practice in the future for low risk groups. There may be a sense of urgency to implement new 420 
approaches but it is vital that we have the evidence to support these implementation decisions. A recent 421 
survey on gynaecology follow-up practices in the UK found that 98% of 117 respondents indicated that 422 
regular scheduled hospital follow-up was the approach most commonly implemented.25 A small minority 423 
reported using nurse-led and telephone approaches with none reporting GP led follow-up practices.25 424 
Providing the evidence that TFU is a non-inferior service could give providers and commissioners 425 
confidence to implement effective approaches while more novel approaches are being evaluated for 426 
quality and safety.  427 
 428 
The recent strategy document for improving cancer outcomes in England over the next five years (2015-429 
2020) argues that stratified follow-up pathways that promote self-management offer a more effective 430 
approach to follow-up than traditional medical models of follow-up13. Positive patient experience is 431 
paramount and nurse specialists have been reported as the most important contributors to positive 432 
patient experience and yet this workforce is not expanding to keep pace with the growing numbers of 433 
cancer survivors. While TFU is an acceptable alternative to hospital based approaches it still has 434 
workforce and cost implications. In 2006 it was reported that a study called FIGURE would investigate 435 
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patient initiated follow-up for endometrial cancer patients26 but this trial did not open for recruitment. 436 
There are trials underway in Europe exploring more minimalist approaches to endometrial cancer 437 
follow-up. The TOTEM trial (Italy) compares different intensity follow-up regimes in two groups: 438 
minimalist (reduced schedule of clinic visits with gynaecological examination and limited investigations - 439 
chest, abdomen, pelvis CT every 12 months in minimalist/high risk group) versus intensive (regular clinic 440 
visits with gynaecological examination and regular investigations - pap tests, Ca125, trans-vaginal and 441 
abdominal ultrasound , and chest, abdomen, pelvis CT) ) based on risk of relapse (high versus low risk) 442 
with overall survival as the primary outcome measure (Clinical Trials Identifier: NCT00916708). The OPAL 443 
trial (Denmark) compares hospital based follow-up (including clinical examination) with a minimalist 444 
approach (patient self-referral and instruction on alarm signals that warrant contact with a health care 445 
professional with fear of recurrence as the primary outcome (Clinical Trials Identifier: NCT01853865)). 446 
As minimalist approaches gain momentum, TFU and HFU may both be considered suitable control arms 447 
for studies that investigate novel approaches to follow-up that effectively meet patient’s needs and 448 
provide positive experiences of care within constrained health care budgets.   449 
 450 
Conclusion 451 
ENDCAT demonstrates that nurse-led TFU can effectively replace doctor-led HFU for the routine follow-452 
up of patients treated for Stage I endometrial cancer. Patients reported greater satisfaction with some 453 
aspects of the process and content of their follow up appointment.   454 
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Figure 1. Trial Flow 
 
 
Notes assessed for eligibility in hospital clinics (n=7292)  
Clinic sessions attended for recruitment (n=455)         
Number of appointments related to endometrial cancer (n=1127) 
Number of patients treated for endometrial cancer (n=829) 
Excluded (n= 570)  Not meeting inclusion criteria (n=399)  Declined to participate (n= 92)  Did not attend (n=34)  Missed/pending (n=45) 
Analysed - STAI  (n=111) 
Excluded from analysis:  Lost to follow-up  (n=13)  STAI questions incomplete (n=5) 
Analysed – satisfaction with information (n=111) 
Excluded from analysis:  Lost to follow-up  (n=13)  Question reply missing (n=5) 
 
Lost to follow-up (n=13)  Died unrelated to cancer (n=1)  Recruited in error (n=1)  Withdrawn at patient request (n=1)  Withdrawn due to cancer recurrence (n=2)  Participant requested no more 
questionnaires (n=4)  Did not return questionnaire (n=4) 
Allocated to intervention (n=129)  Received allocated intervention (n=116)  Did not receive allocated intervention  
o No follow-up appointment (n=5) 
o Hospital follow-up (n=8)  
Lost to follow-up (n=14)  Died unrelated to cancer (n=1)  Withdrawn due to cancer recurrence (n=1)  Participant requested no more 
questionnaires (n=3)   Did not return questionnaire (n=9) 
Allocated to intervention (n=130)  Received allocated intervention (n=126)  Did not receive allocated intervention  
o No follow-up appointment (n=4) 
Analysed - STAI (n=106) 
Excluded from analysis:  Lost to follow-up  (n=14)  STAI questions incomplete (n=10) 
Analysed - satisfaction with information (n=108) 







Telephone group Hospital group 
Table 1.  Characteristics of the study sample.  Data are n (%) unless otherwise stated. 
 Total (n=259) TFU (n=129) HFU (n=130) 
Age at recruitment 
Median (IQR) 65 (58 to 71) 66 (60 to 72·5) 64 (57·8 to 69) 
Marital Status 
Married / co-habiting/civil 
partnership 
195 (75·3%) 95 (73.6%) 100 (76.9%) 
Divorced / separated 17 (6·6%) 8 (6·2%) 9 (6·9%) 
Widowed 31 (12·0%) 16 (12·4%) 15 (11·5%) 
Never married 16 (6·2%) 10 (7·8%) 6 (4·6%) 
Educational Level  




201 (77·9%) 99 (77·3%) 102 (78·5%) 
Degree and above 14 (5·4%) 8 (6·3%) 6 (4·6%) 
Current Employment Status 
Currently Working 97 (37·5%) 43 (33·3%) 54 (41·5%) 
Not Currently Working 162 (62·5%) 86 (66·7%) 76 (58·5%) 
Occupational Classification 
Managers, Directors and 
Senior Officials 
19 (7·6%) 9 (7·2%) 10 (8·0%) 
Professional Occupations 60 (24·0%) 31 (24·8%) 29 (23·2%) 
Associate Professional and 
Technical Occupations 
12 (4·8%) 10 (8·0%) 2 (1·6%) 
Administrative and Secretarial 
Occupations 
54 (21·6%) 25 (20·0%) 29 (23·2%) 
Skilled Trades Occupations 15 (6·0%) 6 (4·8%) 9 (7·2%) 
Caring, Leisure and Other 
Service Occupations 
38 (15·2%) 20 (16·0%) 18 (14·4%) 
Sales and Customer Service 
Occupations 
17 (6·8%) 11 (8·8%) 6 (4·8%) 
Process, Plant and Machine 
Operatives 
5 (2·0%) 2 (1·6%) 3 (2·4%) 
Elementary Occupations 30 (12·0%) 11 (8·8%) 19 (15·2%) 
Ethnic group 
White British 256 (98·8%) 128 (99·2%) 128 (98·5%) 
Indian 2 (0·8%) 1 (0·8%) 1 (0·8%) 
Polish 1 (0·4%) 0 (0·0%) 1 (0·8%) 
Type of surgery received 
Abdominal Hysterectomy 195 (75·3%) 97 (75·2%) 98 (75·4%) 
Vaginal Hysterectomy 7 (2·7%) 6 (4·7%) 1 (0·8%) 
Keyhole Surgery (LAVH) 46 (17·8%) 19 (14·7%) 27 (20·8%) 
Hysterectomy - type unknown 11 (4·2%) 7 (5·4%) 4 (3·1%) 
Received Radiotherapy 
Yes 11 (4·2%) 6 (4·7%) 5 (3·8%) 
Time from diagnosis 
Median (IQR) (months)  12 (4 to 24) 12 (3.5 to 22) 12 (4 to 26) 
Follow-up status at Recruitment 
3-4 months 163 (62·9%) 81 (62·8%) 82 (63·1%) 
6 months 82 (31·7%) 44 (34·1%) 38 (29·2%) 
12 months 14 (5·4%) 4 (3·1%) 10 (7·7%) 
 
Table 2. Satisfaction with aspects of service provision at follow-up by randomised group 














I was kept waiting too long for my 
appointment 
87 (83·7%) 12 (11·5%) 5 (4·8%) 82 (73·9%) 5 (4·5%) 24 (21·6%) 0·001 
The person I saw was able to deal 
with any problems I had  
4 (3·6%) 5 (4·5%)  101 (91·8%) 4 (3·7%) 8 (7·3%) 97 (89·0%) 0·48 
The person I spoke to told me all I 
wanted to know   
2 (1·8%) 5 (4·4%) 107 (93·9%) 4 (3·6%) 8 (7·3%) 98 (89·0%) 0·26 
I was not given enough information 
about my medication (tablets) and 
the side effects 
21 (72·4%) 5 (17·2%) 3 (10·3%) 33 (68·8%) 12 (25·0%) 3 (6·3%) 0·88 
The person I spoke to took no 
interest in me as a person 
104 (91·2%) 3 (2·6%) 7 (6·1%) 96 (86·5%) 6 (5·4%) 9 (8·1%) 0·25 
The person I spoke to gave me a 
chance to say what was really on my 
mind 
2 (1·8%) 4 (3·5%) 107 (94·7%) 7 (6·5%) 6 (5·6%) 94 (87·9%) 0·07 
The person I spoke to paid 
attention to what I was saying 
2 (1·7%) 2 (1·7%) 111 (96·5%) 4 (3·5%) 7 (6·2%) 102 (90·3%) 0·042 
I felt able to express myself and 
ask questions 
0 (0·0%) 4 (3·5%) 110 (96·5%) 6 (5·4%) 6 (5.4%) 99 (89·2%) 0·016 
after talking to the doctor/nurse I felt 
much better about my problems 
1 (0·9%) 18 (17·0%) 87 (82·1%) 5 (5·0%) 23 (22·8%) 73 (72·3%) 0·66 
The person I spoke to did not spend 
enough time talking to me 
103 (91·2%) 5 (4·4%) 5 (4·4%) 99 (87·6%) 8 (7·1%) 6 (5·3%) 0·40 
The person I spoke to really 
seemed to know about my 
particular case and situation 
2 (1·8%) 12 (10·5%) 100 (87·7%) 13 (11·7%) 16 (14·4%) 82 (73·9%) 0·005 
The person I spoke to investigated 
any problems I mentioned to my 
satisfaction 




Table 3. Information needs at follow-up by randomised group. * P-values from Fisher’s exact test reported due to low cell frequencies. 
 
 TFU HFU  
 Yes No Yes No P 
Q17: Information about the cancer diagnosis?   6 (5·3%) 108 (94·7%) 4 (3·5%) 110 (96·5%) 0·75* 
Q18: Information about the different types of treatment, including side 
effects? (e.g. surgery, chemotherapy, radiotherapy 
2 (1·.8%) 109 (98·2%) 1 (0·9%) 110 (99·1%) 1·0* 
Q19: Information about whether your children or other members of the 
family are at risk of getting endometrial (womb) cancer? 
16 (14·3%) 96 (85·7%) 31 (27·7%) 81 (72·3%) 0·10 
Q20: Information about how the treatment may have affected your feelings 
about your body, your sexual attractiveness and sexual function 
7 (6·3%) 105 (93·8%) 12 (10·8%) 99 (89·2%) 0·80 
Q21: Information about caring for yourself? (e.g. diet, support groups, 
finances, psychological support) 
10 (8·8%) 103 (91·2%) 14 (12·4%) 99 (87·6%) 0·12 
Q22: Have you had any concerns about how your family are coping with 
your diagnosis 
4 (3·5%) 110 (96·5%) 5 (4·5%) 106 (95·5%) 0·30 
Q23: Do you need information about anything else not mentioned in 
questions 17-22? 











I got all the information I needed 137 (62·6%) 75 (67·6%) 62 (57·4%) 
I got most of the information I needed 30 (13·7%) 20 (18·0%) 10 (9·3%) 
I got some of the information I needed 6 (2·7%) 1 (0·9%) 5 (4·6%) 
I got none of the information I needed 1 (0·5%) 0 (0·0%) 1 (0·9%) 




Table S2 EORTC QLQ-C30 subscales by randomised group. 
 * Hospital group mean minus telephone group mean, adjusted for age, level of education, occupational group, centre, baseline EORTC C30 score and post-
operative follow-up status (<1 year; ≥1 year). 






















P Adjusted mean 
difference (95% CI) * 
Global health status 
QoL (revised) 
72·9 (19·8) 72·8 (20·0) 73·0 (19·8) 71·6 (19·8) 73·2 (21·5) 0·31 2·1 (-2·0 to 6·2) 
Physical functioning 
(revised) 
76·1 (25·3) 73·6 (27·0) 78·5 (23·3) 76·5 (24·3) 78·5 (24·9) 0·50 -1·3 (-5·0 to 2·4) 
Role functioning 
(revised) 
75·5 (32·2) 72·5 (33·2) 78·5 (31·0) 76·9 (32·6) 82·0 (29·4) 0·44 2·4 (-3·7 to 8·4) 
Emotional functioning 83·3 (19·7) 85·3 (18·2) 81·4 (21·0) 84·6 (19·5) 80·8 (24·0) 0·73 0·8 (-3·7 to 5·3) 
Cognitive functioning 84·6 (19·6) 84·6 (20·3) 84·7 (19·0) 87·0 (16·0) 83·8 (21·4) 0·41 -1·5 (-5·1 to 2·1) 
Social functioning 83·2 (26·8) 83·1 (27·0) 83·3 (26·8) 86·6 (24·7) 85·1 (26·0) 0·82 -0·6 (-6·1 to 4·8) 
Fatigue 27·9 (24·0) 29·6 (25·7) 26·2 (22·3) 29·2 (28·3) 24·9 (25·7) 0·23 -3·2 (-8·4 to 2·0) 
Nausea and vomiting 3·6 (11·4) 2·4 (10·6) 4·7 (12·1) 3·5 (9·7) 4·6 (12·8) 0·83 0·3 (-2·6 to 3·2) 
Pain 21·4 (28·8) 21·3 (28·8) 21·5 (29·0) 21·5 (29·8) 20·1 (30·1) 0·56 -1·8 (-7·8 to 4·3) 
Dyspnoea 14·6 (22·8) 16·4 (24·3) 12·9 (21·1) 17·5 (28·5) 13·2 (23·7) 0·50 -1·9 (-7·4 to 3·6) 
Insomnia 32·1 (32·2) 31·4 (31·7) 32·8 (32·8) 27·3 (31·1) 32·2 (31·8) 0·26 3·5 (-2·5 to 9·5) 
Appetite loss 7·3 (17·8) 7·3 (17·9) 7·2 (17·8) 4·4 (11·3) 4·2 (13·5) 0·60 -0·8 (-3·9 to 2·2) 
Constipation 14·8 (25·8) 13·1 (24·1) 16·5 (27·3) 10·4 (20·9) 15·9 (25·2) 0·035 5·0 (0·4 to 9·6) 
Diarrhoea 5·9 (17·0) 4·1 (13·9) 7·7 (19·5) 3·2 (9·9) 4·4 (13·0) 0·98 0 (-2·7 to 2·8) 
Financial difficulties 7·5 (20·1) 5·0 (14·7) 10·0 (24·0) 4·7 (13·9) 6·5 (20·1) 0·31 -1·8 (-5·3 to 1·7) 
 
 
Table S3. EORTC QLQ-EN24 subscales by randomised group.   
* Hospital group mean minus telephone group mean, adjusted for age, level of education, occupational group, centre, baseline EORTC  score and post-
operative follow-up status (<1 year; ≥1 year). 






















P Adjusted mean 
difference (95% CI) * 
Sexual interest 17·5 (25·0) 14·5 (24·6) 20·5 (25·0) 16·7 (24·6) 21·4 (24·6) 0·41 -2·1 (-7·0 to 2·9) 
Sexual activity 12·8 (21·6) 12·2 (21·8) 13·3 (21·5) 13·1 (24·3) 18·0 (23·6) 0·13 4·0 (-1·1 to 9·0) 
Sexual enjoyment 53·3 (34·3) 51·3 (35·6) 54·9 (33·7) 56·8 (31·8) 61·0 (29·7) 0·20 -7·4 (-18·7 to 3·9) 
Lymphoedema 14·2 (23·5) 17·8 (25·3) 10·6 (21·0) 16·8 (23·7) 11·4 (20·2) 0·47 -1·6 (-6·0 to 2·8) 
Urological symptoms 22·4 (21·1) 23·3 (22·2) 21·6 (20·1) 20·4 (22·0) 18·4 (18·6) 0·64 -0·9 (-4·9 to 3·0) 
Gastrointestinal 
symptoms 
14·5 (17·0) 15·0 (17·7) 14·0 (16·4) 11·3 (12·9) 11·1 (14·6) 0·58 0·8 (-2·0 to 3·5) 
Body image problems 13·1 (25·4) 11·6 (23·5) 14·7 (27·2) 8·0 (16·9) 11·5 (25·3) 0·35 1·9 (-2·1 to 5·9) 
Sexual/vaginal problems 32·4 (29·8) 32·5 (29·8) 32·4 (30·3) 25·9 (28·7) 24·7 (30·8) 0·37 5·0 (-6·0 to 15·9) 
Back/pelvis pain 28·0 (31·3) 27·2 (29·7) 28·8 (32·7) 27·1 (32·1) 24·8 (31·4) 0·13 -4·9 (-11·2 to 1·4) 
Tingling/numbness 15·1 (25·3) 15.9 (27·2) 14.4 (23·4) 16.2 (26·8) 12.6 (21·9) 0·31 -2·8 (-8·2 to 2·6) 
Muscular pain 37·2 (32·8) 37.4 (31·7) 36.9 (34·0) 36.6 (33·2) 31.3 (30·8) 0·11 -5·7 (-12·7 to 1·3) 
Hair loss 4·5 (14·9) 5.2 (16·6) 3.8 (12·9) 5.3 (15·1) 5.3 (14·4) 0·60 0·9 (-2·6 to 4·5) 
Taste change 5·6 (16·3) 6.9 (19·2) 4.3 (12·7) 3.2 (11·7) 1.5 (6.9) 0·29 -1·4 (-3·9 to 1·2) 
 
Note: EORTC QLQ-C30 and QLQ-EN24 have both function and symptom subscales.  For function subscales a higher score indicates a better performance in 
this subscale, so a positive difference in means implies a higher function in the hospital group. For symptom subscales a higher score indicates a higher level 
of symptoms in this subscale, so a positive difference in means implies a higher level of this symptom in the hospital group.   
 
  




TELEPHONE INTERVENTION (ENDCAT TRIAL) 
 
Questions to be asked by Gynaecology Oncology Clinical Nurse Specialist (CNS) at 
telephone consultation 
 
*nb Please re-check patient consent for audio recording* 
 
Patient Name:  ___________________________________________  
Hospital Number:  _________________________________________  
Date of Birth:       
CNS Initials:     
Date:      
Follow-up telephone call (please tick)  
3 months  4 months  6 months  12 months  
Other (please state)  __________________  
 
Hello, this is <name of specialist nurse> phoning for our …….. month follow-up appointment.  
1. How are you doing with …….. (issues related to previous hospital visit/telephone 
appointment)? 
 
 _____________________________________________________________________  
 _____________________________________________________________________  
 _____________________________________________________________________  
 _____________________________________________________________________  
CNS - please tick one box 
Issues remain a problem   Issues partly resolved 
Issues fully resolved    No problems recorded 
Appendix S1 
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2. Since your last follow-up appointment has anything changed? 
 
Yes  No 
 
If yes, what has changed?  
  
  ______________________________________________________________________  
  ______________________________________________________________________  
 
CNS – If yes, was this change in condition addressed over the phone?    
 
Yes (fully)  Yes (partly)   No 
 
Was further action indicated? Yes   No 
 
If yes, what was the course of action? 
 
  ______________________________________________________________________  
  ______________________________________________________________________  
3. Since your last appointment have you noticed any of the following: 
 • Bleeding   Yes  No 
 • Unusual discharge  Yes  No  
 • Unusual aches and pains Yes  No 
 
CNS – if yes to any of the above what was the course of action indicated?  
 
  ______________________________________________________________________  
  ______________________________________________________________________  
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I have a list of things that other people have said they’d like to have information about 
following treatment. Obviously, not all of them will apply to you, but do you mind if we 
work through the list anyway and you can tell me if you need information (or have any 
concerns) about any of these areas? 
 
4. Do you need information about the operation you had?  
 
Yes  No 
 
 
CNS - If yes, what information was needed?  
 
  ______________________________________________________________________  
  ______________________________________________________________________  
 
If yes, was the information need met over the phone?    
 
Yes (fully)  Yes (partly)   No 
 
Was further action indicated? Yes   No 
 
If yes, what was the course of action? 
 
  ______________________________________________________________________  
  ______________________________________________________________________  
5. Do you need more information about your cancer diagnosis?  
 
Yes  No 
 
CNS - If yes, what information was needed?  
 
  ______________________________________________________________________  
  ______________________________________________________________________  
 
If yes, was the information need met over the phone?    
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Was further action indicated? Yes   No 
 
If yes, what was the course of action? 
 
 ______________________________________________________________________ 
 ______________________________________________________________________  
6. If applicable. Do you need information about the other types of treatment you had, 
including side effects (i.e. chemotherapy, radiotherapy)? 
 
Yes  No  Not applicable 
 
CNS - If yes, what information was needed?  
 
 ______________________________________________________________________ 
 ______________________________________________________________________  
 
If yes, was the information need met over the phone?    
 
Yes (fully)  Yes (partly)   No 
 
Was further action indicated? Yes   No 
 
If yes, what was the course of action? 
 
 ______________________________________________________________________ 
 ______________________________________________________________________  
7. Do you have any concerns about whether your children or other members of the 
family are at risk at getting endometrial (womb) cancer?  
 
Yes  No 
 
CNS - If yes, what concerns were expressed?  
 
 ______________________________________________________________________ 
 ______________________________________________________________________  
If yes, was the concern dealt with over the phone?    
 
Yes (fully)  Yes (partly)   No 
 
Was further action indicated? Yes   No 
  
ENDCAT Telephone Intervention Guide.     Page 5 of 8 
 
If yes, what was the course of action? 
 
 ______________________________________________________________________ 
 ______________________________________________________________________  
8. Do you need information about how the treatment may affect your feelings about 
your body and your sexual attractiveness? 
 
Yes  No 
 
CNS - If yes, what information was needed?  
 
 ______________________________________________________________________ 
 ______________________________________________________________________  
If yes, was the information need met over the phone?    
 
Yes (fully)  Yes (partly)   No 
 
Was further action indicated? Yes   No 
 
If yes, what was the course of action? 
 ______________________________________________________________________ 
 ______________________________________________________________________  
9. Do you need information about your sexual function?  
 
Yes  No 
 
CNS - If yes, what information was needed?  
 
 ______________________________________________________________________ 
 ______________________________________________________________________  
If yes, was the information need met over the phone?    
 
Yes (fully)  Yes (partly)   No 
 
Was further action indicated? Yes   No 
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If yes, what was the course of action? 
 ______________________________________________________________________ 
 ______________________________________________________________________  
10. Do you need information about caring for yourself? (e.g. diet and appetite, exercise, 
problems with bowel and urinary function, support groups, complementary therapy, 
finances, psychological support)  
 
Yes  No 
 
CNS - If yes, what information was needed?  
 
 ______________________________________________________________________ 
 ______________________________________________________________________  
If yes, was the information need met over the phone?    
 
Yes (fully)  Yes (partly)   No 
 
Was further action indicated? Yes   No 
 
If yes, what was the course of action? 
 
 ______________________________________________________________________ 
 ______________________________________________________________________  
11. Do you have any concerns about how your family have coped with your diagnosis? 
 
Yes  No 
 
CNS - If yes, what concerns were expressed?  
 
 ______________________________________________________________________ 
 ______________________________________________________________________  
If yes, was the concern dealt with over the phone?    
  
Yes (fully)  Yes (partly)   No 
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If yes, what was the course of action? 
 
 ______________________________________________________________________ 
 ______________________________________________________________________  
12. Is there anything else concerning you? 
 
Yes  No 
 




If yes, was the concern dealt with over the phone?    
  
Yes (fully)  Yes (partly)   No 
 
Was further action indicated? Yes   No 
 
If yes, what was the course of action? 
 
 ______________________________________________________________________ 
 ______________________________________________________________________  
13. CNS – Please arrange next appointment 
 
 
The next telephone follow-up call will be due in …….. months.  
 
Date of next appointment     Time  
 
Please check that patient has contact numbers for gynaecology oncology nursing service. 
 
14. CNS – were any tests/investigation requested? Yes  No 
 
If yes, what tests/investigations were requested? 
 
 ______________________________________________________________________  
 
If yes, why were the tests /investigations requested? 
 
 ______________________________________________________________________  
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15. CNS – were any referrals made?    Yes  No 
 
If yes, what referrals were requested? 
 
 ______________________________________________________________________  
 
If yes, why was a referral necessary? 
 
 ______________________________________________________________________  
 
16. CNS - Additional Comments: 
 
 ______________________________________________________________________  
 ______________________________________________________________________  
 ______________________________________________________________________  
 ______________________________________________________________________  
 ______________________________________________________________________  
 ______________________________________________________________________  
 
